Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Study Details
Study Description
Brief Summary
The primary objective of this study is to evaluate the efficacy of tislelizumab in participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Progression-free Survival (PFS) as assessed by investigator
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Tislelizumab Tislelizumab monotherapy for up to 45 months |
Drug: Tislelizumab
200 mg administered via intravenous (IV) infusion once every 3 weeks
Other Names:
|
| Experimental: Salvage chemotherapy Salvage chemotherapy for up to 45 months |
Drug: Salvage Chemotherapy
Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
|
Outcome Measures
Primary Outcome Measures
- Progression-free Survival (PFS) by Investigator [Up to 45 months]
Time from the date of randomization to the date of progressive disease (PD) or death, whichever occurs first
Secondary Outcome Measures
- Duration of Response (DOR) by Investigator [Up to 45 months]
The time from the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first
- Overall Response Rate (ORR) by Investigator [Up to 45 months]
The proportion of participants who achieves a best overall response of complete response (CR) or partial response (PR)
- Rate of Complete Response (CR) by Investigator [Up to 45 months]
The proportion of participants who achieves a best overall response of CR
- Time to Response (TTR) by Investigator [Up to 45 months]
Time from the date of randomization to the time the response criteria are first met
- Overall survival (OS) [Up to 45 months]
Defined as the time from the date of randomization to the date of death due to any reason
- Number of participants experiencing Adverse Events (AEs) [Up to 45 months]
- Number of participants experiencing Serious Adverse Events (SAEs) [Up to 45 months]
Eligibility Criteria
Criteria
Key Inclusion Criteria:
-
Histologically confirmed cHL.Must have relapsed or refractory ( cHL and
-
Has failed to achieve a response or progressed after autologous hematopoietic stem cell transplant (ASCT). or
-
Has received at least two prior lines of systemic chemotherapies for cHL and is not an ASCT candidate.
-
Must have measurable disease 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Must have adequate organ functions. 5. Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy used to control cancer including locoregional treatment must have been completed ≥ 4 weeks before the first dose of study drug, and all treatment-related adverse events are stable and have either returned to baseline or Grade 0/1
Key Exclusion Criteria:
-
Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma. Known central nervous system (CNS) lymphoma.
-
Prior allogeneic hematopoietic stem cell transplant. ASCT or Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) within 100 days of first dose of study drug.
-
Prior therapies targeting PD-1 or PD-L1.
-
Prior malignancy within the past 3 years except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast.
-
Participant with active autoimmune disease or history of autoimmune disease with high risk of recurrence.
-
Serious acute or chronic infection requiring systemic therapy.
-
Known human immunodeficiency virus (HIV), or serologic status reflecting active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing Cancer Hospital | Beijing | Beijing | China | 100142 |
| 2 | Quanzhou First Hospital Affiliated to Fujian Medical University | Quanzhou | Fujian | China | 362002 |
| 3 | Harbin Medical University Cancer Hospital | Harbin | Heilongjiang | China | 150081 |
| 4 | Henan Cancer Hospital | Zhengzhou | Henan | China | 450008 |
| 5 | Hunan Cancer Hospital | Changsha | Hunan | China | 410013 |
| 6 | Jilin Cancer Hospital | Changchun | Jilin | China | 130012 |
| 7 | Zhejiang Cancer Hospital | Hangzhou | Zhejiang | China | 310022 |
Sponsors and Collaborators
- BeiGene
Investigators
- Study Director: Xia Zhao, MD, BeiGene
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BGB-A317-314
- CTR20201517